Evidence map›Paper›PMID 40742165›Full record

ArticleMicrobiology spectrum2025

Evaluation of mlstverse system for accurate subspecies identification and drug resistance prediction in

Wakako Arakaki, Takeshi Kinjo, Wakaki Kami, Hiroe Hashioka, Daijiro Nabeya, Hiroaki Nagano, Shiomi Yoshida, Kazunari Tsuyuguchi, Yuki Matsumoto, Shota Nakamura and 2 more

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wakako ArakakiDepartment of First Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
Takeshi KinjoDepartment of First Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.ORCID 0000-0002-0262-0401
Wakaki KamiDepartment of First Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
Hiroe HashiokaDepartment of First Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.
Daijiro NabeyaDepartment of First Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.ORCID 0000-0001-5566-7310
Hiroaki NaganoDepartment of Respiratory Medicine, Okinawa Prefectural Chubu Hospital, Okinawa, Japan.
Shiomi YoshidaClinical Research Center, NHO Kinki Chuo Chest Medical Center, Osaka, Japan.ORCID 0000-0002-8197-3829
Kazunari TsuyuguchiClinical Research Center, NHO Kinki Chuo Chest Medical Center, Osaka, Japan.
Yuki MatsumotoDepartment of Infection Metagenomics, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan.
Shota NakamuraDepartment of Infection Metagenomics, Research Institute for Microbial Diseases (RIMD), Osaka University, Osaka, Japan.
Jiro FujitaRespiratory Medicine, Ohama Dai-ichi Hospital, Okinawa, Japan.
Kazuko YamamotoDepartment of First Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine, Okinawa, Japan.

Funding

Japan Society for the Promotion of Science 23K07925Research Institute for Microbial Diseases, Osaka University JRPRIMD24B12
6 · The paper itself

Abstract

Accurate subspecies identification and drug susceptibility testing (DST) are essential for appropriate clinical management, particularly in patients infected with IMPORTANCE: Accurate subspecies identification and drug susceptibility testing (DST) are essential for appropriate clinical management of

Indexed as

Drug Resistance, BacterialMultilocus Sequence TypingMycobacterium abscessusMycobacterium Infections, NontuberculousAmikacinAnti-Bacterial AgentsClarithromycinHumansMicrobial Sensitivity TestsSoftwareAmikacinAnti-Bacterial AgentsClarithromycinamikacindrug resistancemacrolidemlstversemultilocus sequence typingMycobacterium abscessus speciesnontuberculous mycobacteriasubspecies

Identifiers

PMID40742165
PMCPMC12403713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.